Tevogen (TVGN) Cash & Equivalents (2021 - 2026)

Tevogen Bio Holdings (TVGN) has 6 years of Cash & Equivalents data on file, last reported at $692305.0 in Q1 2026.

• Quarterly Cash & Equivalents fell 64.95% year-over-year to $692305.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $692305.0 (down 64.95% YoY) and the FY2025 annual result came in at $552372.0, down 56.95% from the prior year.
• Cash & Equivalents advanced to $692305.0 in Q1 2026, from $552372.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $5.7 million in Q1 2023 to a low of $143047.0 in Q3 2022.
• A 5-year average of $1.8 million and a median of $1.1 million in 2024 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 2350.54% in 2023, down 80.81% in 2023.
• Tracing TVGN's Cash & Equivalents over 5 years: stood at $5.5 million in 2022, then tumbled by 80.81% to $1.1 million in 2023, then rose by 21.91% to $1.3 million in 2024, then plunged by 56.95% to $552372.0 in 2025, then grew by 25.33% to $692305.0 in 2026.
• The last three Cash & Equivalents figures came in at $692305.0 (Q1 2026), $552372.0 (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.